Drug Price Trends for EMVERM

Average Pharmacy Cost for EMVERM

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
EMVERM 100 MG TABLET CHEW	64896-0669-30	650.01305	EACH	2025-01-22
EMVERM 100 MG TABLET CHEW	64896-0669-30	714.77121	EACH	2025-01-20
EMVERM 100 MG TABLET CHEW	64896-0669-30	650.38327	EACH	2024-12-18
EMVERM 100 MG TABLET CHEW	64896-0669-30	650.22979	EACH	2024-11-20
EMVERM 100 MG TABLET CHEW	64896-0669-30	648.42109	EACH	2024-10-23
EMVERM 100 MG TABLET CHEW	64896-0669-30	651.23548	EACH	2024-09-18

Market Analysis and Price Projections for EMVERM (Mebendazole)

Market Overview

The market for EMVERM, a prescription anti-worm medication containing mebendazole, is driven by several key factors. Mebendazole, a broad-spectrum anthelmintic, is widely used to treat infections caused by worms such as hookworm, roundworm, whipworm, and pinworm. The global demand for mebendazole tablets, including EMVERM, has been increasing due to the rising prevalence of parasitic infections and the growing focus on preventive healthcare and deworming treatments[1].

Market Drivers

Increasing Prevalence of Parasitic Infections

The global market for mebendazole tablets, including EMVERM, is fueled by the increasing prevalence of soil-transmitted helminthiases (STH) infections worldwide. Public health initiatives and mass drug administration programs in endemic regions, particularly in sub-Saharan Africa, Southeast Asia, and parts of Latin America, have significantly increased the demand for these medications[1].

Growing Focus on Preventive Healthcare

The emphasis on preventive healthcare and the integration of deworming programs with other public health initiatives have boosted the use of mebendazole tablets. Regular deworming practices in schools and communities have contributed to the market's expansion[1].

Technological Advancements

Pharmaceutical companies are investing in research and development to create novel drug delivery systems and explore potential new indications for mebendazole. This includes the development of improved formulations such as long-acting or controlled-release versions, which could enhance efficacy and patient compliance[1].

Market Opportunities

Improved Formulations and Combination Therapies

There is a growing interest in developing improved versions of mebendazole, such as extended-release formulations or combination therapies. These innovations could enhance efficacy, reduce dosing frequency, and improve patient compliance, particularly in mass drug administration programs[1].

New Indications

Research has suggested potential applications of mebendazole beyond its current use as an anthelmintic. For example, some studies indicate that mebendazole may have anti-tumor properties, particularly against certain types of brain tumors and colorectal cancer. If further research confirms these findings and leads to regulatory approvals, it could open up entirely new markets for EMVERM[1].

Price Analysis

Current Pricing

The cost of EMVERM varies depending on the pharmacy and the availability of discounts. On average, the retail price for a 100 mg oral tablet, chewable, is around $702 to $855. However, with discounts and coupons, the price can be significantly reduced. For instance, using SingleCare's Emverm coupon, the price can drop to around $632 to $653 per tablet[2][5].

Price Projections

Given the increasing demand driven by public health initiatives and the growing focus on preventive healthcare, the prices of EMVERM are likely to remain stable or see moderate increases. However, the market may face challenges such as increasing generic competition, which could lead to price pressures, particularly in developing markets[1].

Competitive Landscape

Generic Competition

The market for mebendazole tablets, including EMVERM, faces competition from generic versions. Generic Emverm is available at a lower price point compared to the branded version, which could impact the market dynamics and pricing strategies of pharmaceutical companies[2][5].

Brand Differentiation

Companies like Impax, which received approval for EMVERM in 2016, differentiate their products through high clinical cure rates and convenient dosing regimens. For example, EMVERM offers a 95% clinical cure rate in a single 100 mg dose, making it a preferred treatment option for pinworm and other worm infections[3][4].

Regional Market Analysis

Emerging Economies

Emerging economies present significant growth opportunities for the mebendazole market. The expansion of healthcare infrastructure and increasing healthcare expenditure in these regions are expected to improve access to anthelmintic treatments, driving market growth[1].

Developed Markets

In developed markets, the focus on preventive healthcare and the integration of deworming programs with other public health initiatives continue to support the demand for EMVERM. However, these markets may face more intense competition from generic versions and other anthelmintic medications[1].

Challenges and Risks

Drug Resistance

The potential development of drug resistance in parasites could necessitate the creation of new anthelmintic treatments, potentially impacting the long-term market dynamics for EMVERM. This underscores the need for continuous research and development to address emerging challenges[1].

Regulatory Environment

Changes in regulatory environments and healthcare policies can also impact the market. Companies must navigate these complexities to maintain market share and ensure continued access to their products[1].

Key Takeaways

• The mebendazole tablet market, including EMVERM, is expected to witness significant growth driven by increasing parasitic infections and public health initiatives.
• Technological advancements in drug formulations and potential new indications for mebendazole are key opportunities for market expansion.
• Generic competition and the potential for drug resistance are significant challenges that market players must address.
• Emerging economies offer substantial growth opportunities due to expanding healthcare infrastructure and increasing healthcare expenditure.
• The focus on preventive healthcare and integration with public health initiatives will continue to drive demand for EMVERM.

FAQs

1. What is EMVERM used for? EMVERM is a prescription anti-worm medication used to prevent and treat infections caused by worms such as hookworm, roundworm, whipworm, and pinworm. It contains mebendazole as the active ingredient[2][3].

2. How does EMVERM work? EMVERM works by preventing the worms from absorbing sugars, which they need to survive. This mechanism of action leads to the death of the worms and the resolution of the infection[2].

3. What is the average retail price of EMVERM? The average retail price of EMVERM is around $702 to $855 for a 100 mg oral tablet, chewable, depending on the pharmacy. However, discounts and coupons can significantly reduce this cost[2][5].

4. What are the potential new indications for mebendazole? Research has suggested potential applications of mebendazole in treating certain types of brain tumors and colorectal cancer. If further research confirms these findings, it could open up new markets for EMVERM[1].

5. What are the challenges facing the mebendazole market? The market faces challenges such as increasing generic competition, potential drug resistance in parasites, and the need to navigate complex global health landscapes and regulatory environments[1].

Sources

1. DataHorizon Research: Mebendazole Tablet Market Size, Growth and Analysis Report - 2033.
2. SingleCare: Emverm Coupons 2025: Up to 80% Discount.
3. PR Newswire: Impax Receives Approval of EMVERM™ (mebendazole) Chewable Tablets 100 mg.
4. Amneal Investors: Impax Receives Approval of EMVERM™ (mebendazole) Chewable Tablets 100 mg.
5. Drugs.com: Emverm Prices, Coupons, Copay Cards & Patient Assistance.